<p>The calculated tumor volume V (○) and the measured normalized total fluorescence intensity FI (♦) were plotted over time. Each plot represents one treated individual. Day of chemotherapy is marked with a vertical line (d29 or d26 post cell implantation, respectively). In the last row representative intensity weighted overlay images are shown corresponding to the plots in the row above.</p
<p>A) Representative western blots of activated or phosphorylated EGFR (pEGFR, tyr1068) in OVCA 433 ...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>)Fluorescence intensity map a...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>) Fluorescence intensity map ...
A continuous monitoring of the whole tumor burden of individuals in orthotopic tumor models is a des...
<p>Combination therapy was given i. p. in two cycles (d0 - d3 & d21 - d24): On the first day the ani...
<p>(A) The growth curves of CT-26 xenografts after transplantation into BALB/c nude mice treated wit...
<p>Representative data sets of one and two tumors expressing eGFP (A) or dsRed2 (B) are displayed. T...
Figure S1. The phosphorescence intensity of tumor imaging of CT-26 xenografts after transplantation ...
Figure 4b. The phosphorescence intensity of tumor imaging of CT-26 xenografts after transplantation ...
<p>Luciferase-labeled EGFR-negative cells (SW620-LUC), EGFR-positive cells (HCT116) or equal numbers...
<p>The cisplatin was used as an anti-tumor agent, and saline was injected as a contrast (n = 6). Sca...
<p>FDG uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=8 tumors...
F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of ...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>)Fluorescence intensity map a...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>)Fluorescence intensity map a...
<p>A) Representative western blots of activated or phosphorylated EGFR (pEGFR, tyr1068) in OVCA 433 ...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>)Fluorescence intensity map a...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>) Fluorescence intensity map ...
A continuous monitoring of the whole tumor burden of individuals in orthotopic tumor models is a des...
<p>Combination therapy was given i. p. in two cycles (d0 - d3 & d21 - d24): On the first day the ani...
<p>(A) The growth curves of CT-26 xenografts after transplantation into BALB/c nude mice treated wit...
<p>Representative data sets of one and two tumors expressing eGFP (A) or dsRed2 (B) are displayed. T...
Figure S1. The phosphorescence intensity of tumor imaging of CT-26 xenografts after transplantation ...
Figure 4b. The phosphorescence intensity of tumor imaging of CT-26 xenografts after transplantation ...
<p>Luciferase-labeled EGFR-negative cells (SW620-LUC), EGFR-positive cells (HCT116) or equal numbers...
<p>The cisplatin was used as an anti-tumor agent, and saline was injected as a contrast (n = 6). Sca...
<p>FDG uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=8 tumors...
F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of ...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>)Fluorescence intensity map a...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>)Fluorescence intensity map a...
<p>A) Representative western blots of activated or phosphorylated EGFR (pEGFR, tyr1068) in OVCA 433 ...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>)Fluorescence intensity map a...
<p>(<b>A</b>) Fluorescence intensity map at the tumor region. (<b>B</b>) Fluorescence intensity map ...